Research programme: small molecule antibacterials - X-Biotix Therapeutics
Latest Information Update: 04 May 2021
At a glance
- Originator X-Biotix Therapeutics
- Developer Harvard Medical School; X-Biotix Therapeutics
- Class Antibacterials; Small molecules
- Mechanism of Action Bacterial growth modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gram-negative infections
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 04 May 2021 Discontinued for Gram-negative infections in USA (unspecified route)
- 26 Apr 2021 Research programme: small molecule antibacterials - X-Biotix Therapeutics is available for licensing as of 26 Apr 2021. www.x-biotixrx.com
- 30 May 2017 X-Biotix in-licenses technology from Harvard Medical School for development of small molecule antibacterials